Hydroxychloroquine is one of the more misunderstood medicines in modern practice—familiar to millions of patients with lupus and rheumatoid arthritis for decades, yet thrust into public debate for reasons that had little to do with what the drug actually does. This article sets out, plainly and without hype, what hydroxychloroquine is, how it works at the cellular and molecular level, what that mechanism does and does not explain about its uses, and where the clinical evidence is strong versus where it is thin or has been settled by large trials.

What Hydroxychloroquine Is

Hydroxychloroquine (sold under the brand name Plaquenil, among generic equivalents, and commonly prescribed in 200 mg tablets—hence "HCQ 200mg") is a synthetic 4-aminoquinoline. It was developed as a less toxic derivative of chloroquine, which was itself synthesized in the 1930s from research into quinine, the antimalarial alkaloid extracted from the bark of the South American cinchona tree. It is worth pausing on that lineage: a medicine still relied upon today by patients with serious autoimmune disease traces its origin to a compound the created world had already supplied, long before any laboratory improved upon it. Hydroxychloroquine is FDA-approved for three things: treatment and suppression of malaria caused by susceptible strains of Plasmodium, treatment of chronic discoid and systemic lupus erythematosus, and treatment of rheumatoid arthritis in adults. It is not a cure for any of these conditions; it is a disease-modifying agent that reduces disease activity over time.

The Molecular Mechanism: A Weak Base That Changes Cell Chemistry

The central, well-established fact about hydroxychloroquine is that it is a weak base that becomes trapped inside acidic compartments of the cell—principally the lysosome, the endosome, and, in the malaria parasite, an equivalent digestive vacuole. Outside these compartments, at the neutral pH of blood and cytoplasm, the drug exists largely in an uncharged form that crosses cell membranes freely. Once it diffuses into an acidic compartment, it picks up a proton, becomes charged, and can no longer diffuse back out. This is called "lysosomotropic trapping," and it is the single mechanistic thread that ties together nearly everything hydroxychloroquine does in the body.

The practical effect of this trapping is that hydroxychloroquine accumulates to very high concentrations inside lysosomes and raises the pH within them—making these normally acidic compartments less acidic than they should be. Lysosomes depend on their acidity to do their job: breaking down proteins, processing material taken in from outside the cell, and preparing fragments of foreign or self-protein for presentation to the immune system. When hydroxychloroquine blunts that acidity, several downstream effects follow, each of which has been demonstrated in laboratory and cell-based research at institutions studying immune pharmacology over several decades:

None of this makes hydroxychloroquine a broad immunosuppressant in the way that, say, high-dose corticosteroids or chemotherapy-derived drugs are. Its effect is better described as immunomodulatory: it turns down specific overactive signaling pathways rather than shutting down immune function wholesale, which is part of why it has a comparatively gentle long-term side-effect profile relative to many other agents used in autoimmune disease.

Why This Mechanism Explains the Antimalarial Use

In malaria, the mechanism operates on a parasite rather than on the patient's own immune cells, and it is somewhat different in detail. The Plasmodium parasite, once inside a red blood cell, digests hemoglobin for nutrients and must dispose of a toxic byproduct called heme. It does this by polymerizing heme into an inert crystal called hemozoin, inside its own acidic digestive vacuole. Chloroquine and hydroxychloroquine concentrate in that vacuole through the same lysosomotropic trapping described above, and there they interfere with hemozoin formation, allowing toxic free heme to accumulate and kill the parasite. This mechanism has been characterized in parasitology research going back decades and is one of the more thoroughly worked-out drug mechanisms in infectious disease. Its major limitation in practice is resistance: many Plasmodium falciparum strains, particularly in parts of Africa and Southeast Asia, have evolved to pump the drug back out of the digestive vacuole, which is why chloroquine and hydroxychloroquine are no longer reliable choices in much of the malaria-endemic world and travelers should always confirm regional resistance patterns with a physician before relying on either drug for prevention.

The Evidence Base in Lupus and Rheumatoid Arthritis

The clinical case for hydroxychloroquine in lupus is unusually solid for a drug of its age. A frequently cited randomized, double-blind trial conducted by the Canadian Hydroxychloroquine Study Group and published in the New England Journal of Medicine in 1991 took patients with stable lupus already on hydroxychloroquine and randomized half to continue the drug and half to switch to placebo. Those withdrawn from the drug flared significantly more often and more quickly than those who stayed on it—a design that demonstrates ongoing benefit rather than mere correlation. Subsequent long-term observational research, including work associated with lupus cohorts at academic centers such as Johns Hopkins, has linked continuous hydroxychloroquine use with fewer flares, reduced organ damage accumulation, and even a modest survival advantage in lupus patients, though observational data of this kind cannot fully rule out the possibility that healthier or more adherent patients were also more likely to stay on the medication.

In rheumatoid arthritis, hydroxychloroquine is considered one of the milder disease-modifying antirheumatic drugs (DMARDs). Trials from the 1990s onward have generally shown it produces real but modest improvement in joint symptoms compared with placebo, and it is frequently used in combination with other DMARDs such as methotrexate and sulfasalazine rather than alone in more active disease. It is not considered strong enough, on its own, for aggressive or erosive rheumatoid arthritis, and rheumatologists typically reserve it for milder disease or as one component of combination therapy.

The COVID-19 Question, Answered Honestly

Hydroxychloroquine's antiviral plausibility was tested early in the COVID-19 pandemic partly because the same lysosomal alkalinization that dampens immune signaling was also shown, in laboratory cell-culture studies published in 2020, to reduce entry and replication of SARS-CoV-2 in certain cell lines. That in vitro signal generated genuine scientific interest and led to rapid clinical testing. It did not hold up. The RECOVERY trial, a large randomized controlled trial run by the University of Oxford, found in results reported in 2020 that hydroxychloroquine given to hospitalized COVID-19 patients produced no reduction in mortality and was associated with a longer hospital stay compared with usual care; the hydroxychloroquine arm was stopped early for futility. The World Health Organization's SOLIDARITY trial, a large multinational randomized study, reached a similar conclusion and also discontinued its hydroxychloroquine arm. On the strength of this randomized evidence, the U.S. Food and Drug Administration revoked its emergency use authorization for hydroxychloroquine in COVID-19 in June 2020, and it is not approved for that use. This is a case where being honest about the evidence matters more than being agreeable to any particular narrative: an early laboratory finding pointed one direction, and well-conducted human trials pointed the other. Patients deserve that full picture, and informed conversation with one's own physician remains the right way to weigh any off-label use of any medication.

Safety, Monitoring, and Practical Stewardship

Hydroxychloroquine is generally well tolerated, which is part of why it has remained a mainstay for chronic autoimmune disease for so long. The most clinically significant long-term risk is retinopathy—damage to the retina that is rare but cumulative with dose and duration of use, and which can be largely caught early through regular ophthalmologic screening, a responsibility patients and prescribers share as a matter of ordinary diligence. Other effects can include gastrointestinal upset, skin changes, and, at higher doses, effects on heart rhythm (QT prolongation), which is one reason dosing and cardiac history matter and why self-directed or unsupervised use of any prescription medicine is unwise. None of this diminishes the drug's value where it is indicated; it simply underscores that even a well-tolerated, decades-old medicine deserves the same respect, monitoring, and physician partnership as any other.

Key takeaway: Hydroxychloroquine works by making immune cells' acidic compartments less acidic, which calms specific overactive signaling in autoimmune disease and starves the malaria parasite of a detoxification step it needs—mechanisms with strong human trial support in lupus and rheumatoid arthritis, but which did not translate into benefit for COVID-19 in large randomized trials.